Newly discovered vulnerability in an aggressive breast cancer provides therapeutic target

(Beth Israel Deaconess Medical Center) Triple-negative breast cancer quickly becomes resistant to current therapies, leaving patients no therapeutic options. BIDMC researchers discovered that TNBC cells increase production of pyrimidine nucleotides in response to traditional chemotherapy. Discovery represents a vulnerability that can be exploited by blocking pyrimidine using an existing inhibitor in combination with chemotherapy.